Majed Al Fayi is a third year PhD student in molecular pathology at the age of 31 from the University of Liverpool. He has completed his MSc degree in biomedical sciences in 2011 from Hull University. He is a co-author in a paper published in Oncotarget.
Although a large number of studies have been performed on the promoting role of FABP5 in malignant progression of prostate cancer, the possible involvement of other FABP family proteins is not clear. In this work we have first measured the expression levels of 10 members of FABP family in six human prostate cancer cell lines with q-PCR technique and found that FABP9 is one of the most differentially expressed between the benign and the malignant cells. Western blot analysis showed that FABP9 protein was highly expressed in highly malignant cell lines PC3 and PC3-M. Whereas in the benign PNT2 cells and in low or moderately malignant cell lines LNCaP, 22RV1 and DU145, no FABP9 expression was detected. Immunocytochemical analysis in an archival set of prostate tissues showed that the expression level of FABP9 was significantly higher in carcinoma tissues than that in BPH. In carcinomas, the increased expression of FABP9 was significantly associated with the increasing malignancy. While the increased expression of FABP9 was significantly associated with the increased Gleason scores and the AR level, it was significantly correlated with the reduced patient survival. Suppressing FABP9 expression in highly malignant PC3-M cells inhibited invasiveness of prostate cancer cells. Our results suggest that FABP9 is a useful prognostic marker to predict the outcome of prostate cancer patients and it may play a role in promoting invasiveness of the cancer cells.
Julia Alejandra Pezuk has completed her PhD from Sao Paulo University and is currently doing her Post-doctoral studies at Educational and Research Sirio-Libanes Institute in Sao Paulo, Brazil. She has published more than 20 papers in reputed journals and has been serving as a Scientific Reviewer. She has participated in different scientific events and discussions, has lectured speeches and courses, and has also been part of organizing committee in scientific events. She has monitored scientific lab activity during internships and has co-supervised undergraduate students. She collaborates with many scientific projects in the cancer field.
Breast cancer (BC) is the second most common tumors in women and its late diagnosis makes it responsible for the majority of cancer deaths in females. Mammography is an x-ray picture of breast, used to check for BC, its routinary used has improved early detection and identification of this neoplasia. Breast lesion images are classified according to tissue density in 7 different categories known as BI-RADS 0-6. However this system is not accurate to classify lesion in category 3 and 4, where a suspicious of BC is determined but further examines are needed to confirm the diagnosis. Recently has been described that human serum/plasma contains a large number of circulating microRNAs (miRNAs). Alteration on circulating miRNA expression pattern has been related to several pathological conditions, including cancer. Here, we analyzed circulating miRNAs as molecular markers to differentiate benign from malignant breast lesion according to BI-RADS categories. In order to do so, we studied the expression pattern of 72 plasma samples of patients with BI-RADS 1 or 2 (non-cancer patients) and 46 plasma samples of patients with BI-RADS 5 or 6 (cancer patients), and for the validation, we have included 29 patients samples of each group. We then compared the miRNAs' expression profile to find alteration capable of distinguished patients with cancer from those without. We analyzed over 1800 mature miRNA using the miRNome PCR array v18.0 (Qiagen®), and then we tested the 13 miRNAs found alteded in all analysis by qRT-PCR. In the first analysis set (30 control + 13 cancer sample), we found three miRNA up regulated in the cancer groups with a p<0.05, while in the second set (44 controls + 33 cancer samples), we found 7 miRNAs with a difference of at least 1.5x and a p value of <0.05. When we combined the two groups we were able to identify 2 miRNAs that are up regulated in more than 1.5x and with a p<0.05 in the cancer group with respect to the control group, and also another 2 miRNAs with a difference over 1.5X among groups. In the validation group, we were able to confirm the differential expression of both miRNA found in the consolidated group, and also of another 2 miRNAs. We now intend to test these differences in the plasma of BI-RADS 4 patients, to verify the efficacy of these circulating miRNAs in identifying patients who certainly have malignant lesion from those BI-RADS 4 with benign lesions.